Nanomedicine: Nanotechnology, Biology and Medicine
Volume 5, Issue 1 , Pages 46-54, March 2009

In vivo studies of polyacrylate nanoparticle emulsions for topical and systemic applications

Center for Molecular Diversity in Drug Design, Discovery, and Delivery, Department of Chemistry, University of South Florida, Tampa, Florida, USA

Received 18 February 2008; accepted 8 July 2008. published online 29 September 2008.

Abstract 

We have recently reported on a new nanomedicine containing antibiotic-conjugated polyacrylate nanoparticles, which has shown activity against methicillin-resistant Staphylococcus aureus (MRSA) in vitro and no cytotoxicity toward human dermal cells. The water-based nanoparticle emulsion is capable of solubilizing lipophilic antibiotics for systemic administration, and the nanoparticle drug delivery vehicle has shown protective properties for antibiotics from hydrolytic cleavage by bacterial penicillinases, thus rejuvenating the drug's activity against resistant microbes such as MRSA. Here we report the first in vivo study of this penicillin-conjugated nanoparticle emulsion in determining toxicological responses initiated upon systemic and topical application in a murine model. Favorable results were observed in vivo upon both routes of administration and, when topically applied to a dermal abrasion model, the emulsion enhanced wound healing by an average of 3 to 5 days. This study suggests that polyacrylate nanoparticle-containing emulsions may afford promising opportunities for treating both skin and systemic infections.

Key words: In vivo, Nanoparticle, Toxicity, Penicillin, MRSA

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 10.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The authors would like to thank the US Army Medical Research Institute for Infectious Diseases for assistance with the ELISA experiments and the staff at the USF College of Medicine vivarium for their help with the animal experiments.

 All work presented in the manuscript was funded by a single National Science Foundation STTR grant (NSF 0419903) under a joint venture with Nanopharma Technologies, Inc. and the University of South Florida (USF). The technology described in this article is covered under a provisional patent obtained by E.T. through the USF Patents and Licensing Office (USF 03A018PR) and the International Patent Application (International Publication Number PCT WO 03A018PRCWO) are now licensed by Nanopharma Technologies, Inc.

PII: S1549-9634(08)00119-6

doi:10.1016/j.nano.2008.07.004

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 5, Issue 1 , Pages 46-54, March 2009

Article Tools

* Image Usage & Resolution